Extendicare (TSE:EXE) Hits New 52-Week High – Here’s What Happened

Extendicare Inc. (TSE:EXEGet Free Report)’s share price hit a new 52-week high on Tuesday . The stock traded as high as C$11.35 and last traded at C$11.31, with a volume of 84376 shares changing hands. The stock had previously closed at C$11.12.

Analysts Set New Price Targets

EXE has been the subject of several recent analyst reports. BMO Capital Markets set a C$11.00 target price on Extendicare and gave the company a “market perform” rating in a research note on Thursday, January 30th. Royal Bank of Canada raised their target price on Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a research note on Thursday, November 28th. Finally, TD Securities raised their target price on Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a research note on Thursday, November 14th.

Check Out Our Latest Stock Analysis on Extendicare

Extendicare Stock Up 2.0 %

The firm has a market capitalization of C$946.52 million, a price-to-earnings ratio of 14.46 and a beta of 1.26. The stock has a 50 day moving average of C$10.44 and a 200 day moving average of C$9.50. The company has a quick ratio of 0.98, a current ratio of 0.62 and a debt-to-equity ratio of 283.02.

Extendicare Dividend Announcement

The company also recently declared a monthly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 17th will be paid a $0.04 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.48 dividend on an annualized basis and a yield of 4.23%. Extendicare’s dividend payout ratio (DPR) is 61.20%.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.

See Also

Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.